CNC vs ELV: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CNC and ELV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CNC and ELV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Centene Corporation is a St. Louis-based managed-care organization that administers government-sponsored and subsidized health insurance. It is the largest Medicaid managed-care company in the country (roughly 12.5 million members across about 30 states), the top carrier on the Affordable Care Act Marketplace (around 5.5 million members), and a meaningful Medicare player with about 1.0 million Medicare Advantage members plus roughly 8.1 million prescription-drug-plan members. The company reported total revenue of about $194.8 billion in 2025 and about $180 billion over the trailing twelve months to June 2026, and the vast majority of that flows from Medicaid, Marketplace (commercial), and Medicare premiums, making Centene highly exposed to federal and state healthcare policy, reimbursement rates, and medical cost trends.

Full CNC guide

Elevance Health (formerly Anthem) is a diversified health insurer and healthcare services company that covers roughly 45.6 million medical members as of mid 2025. Its Health Benefits segment sells commercial, Medicare Advantage, Medicaid, and ACA marketplace plans, operating Blue Cross Blue Shield plans across 14 states, while its fast-growing Carelon segment houses pharmacy benefits (CarelonRx) and risk-based care services. Operating revenue reached roughly $197.6 billion in 2025, with Carelon revenue climbing about 33 percent on CarelonRx growth and the CareBridge acquisition.

Full ELV guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CNC drivers: Medicaid scale and margin recovery; Marketplace leadership and repricing.
• ELV drivers: Carelon services and pharmacy expansion; Government programs repricing.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Centene withdrew its 2025 guidance and its stock fell roughly 40% in a single day in July 2025 after actuaries flagged that its ACA Marketplace assumptions were too aggressive, so guidance credibility and forecasting accuracy remain live concerns even after two strong 2026 quarters. For ELV, the dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CNC if you believe its drivers more; ELV if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CNC and ELV guides.

CNC. Centene trades near 13 times forward earnings and about 0.19 times sales, still a discount to higher-margin managed-care peers even after a 95% one-year gain. The trailing P/E is not meaningful because of the 2025 loss, so the valuation rests on whether 2026 EPS near $4.88 and 2027 estimates near $5.35 hold. Health insurance is a thin-margin business, so small changes in the health-benefits ratio move earnings sharply.

ELV. Elevance still trades at a modest multiple for a company of its size, though the 2026 rally has lifted it to about 14.5x forward earnings. Q2 2026 was the second straight quarter of large beats (adjusted EPS $7.45 vs ~$6.21, after $12.58 vs ~$10.81 in Q1), but consensus calls for weaker second-half earnings, so the October 21 Q3 report (consensus EPS ~$4.69 on ~$49.2 billion revenue) matters for whether the rerating holds. These figures are approximate and as of October 16, 2026.

Headline figures (approximate, October 2026): CNC shows revenue (ttm) ~$180B, revenue growth (q2 2026, yoy) ~4.6%, q2 2026 adjusted eps ~$2.51 (est. ~$1.08), net income (ttm) ~-$5.1B (2025 charges); ELV shows revenue (ttm) ~$201 billion, q2 2026 revenue ~$49.8 billion; adjusted EPS $7.45 vs ~$6.21 est., net income (ttm) ~$5.0 billion (GAAP EPS ~$22.59), fy2026 adjusted eps guidance at least ~$26.75; consensus ~$27.24.

CNC and ELV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CNC and ELV exposure against your real portfolio. It is not an investment adviser.